The Age
·general
·1 hour ago
WA biotech duo takes aim at diabetes beyond Ozempic
A Western Australian biotech duo is developing RNA-based therapies to treat type 2 diabetes beyond existing GLP-1 drugs like Ozempic. ProGenis Pharmaceuticals and Perth-based Syngenis Labs are using antisense oligonucleotide technology to target insulin resistance at the cellular level. The approach aims to address fundamental molecular drivers that GLP-1 therapies cannot fully correct.
Summary by Glance · The Age
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI